ADHD medicine may be part of how you manage work, appointments, routines and everyday safety. When pregnancy enters the picture, deciding whether to keep taking it can feel much bigger than a simple yes or no.
Taking dexamfetamine, lisdexamfetamine or methylphenidate does not automatically mean treatment must stop before you try to conceive. The useful next step is a preconception review of the exact medicine, dose and support it provides, not a fixed washout period found online.
Australian treatment commonly includes dexamfetamine, which is also called dexamphetamine, lisdexamfetamine such as Vyvanse, and methylphenidate such as Ritalin, Ritalin LA and Concerta. Most research examines pregnancy outcomes rather than ovulation, egg quality, implantation or time to pregnancy, so those questions need to be kept separate.
Quick answers about ADHD medication and fertility
Does ADHD medication affect female or male fertility?
Research has not established that prescribed dexamfetamine, lisdexamfetamine or methylphenidate causes female or male infertility. Direct evidence on ovulation, egg quality, implantation and time to pregnancy is limited. A 2026 male study found modestly lower semen volume with stimulant exposure but no significant differences in sperm concentration, motility or total counts.
Should you stop dexamphetamine or Vyvanse before trying to conceive?
Not automatically. Some people continue, reduce, switch or stop treatment after an individual review. There is no universal waiting period because the exact medicine, dose, ADHD severity, side effects and risks of reduced symptom control all matter.
What should you do if you get a positive pregnancy test while taking ADHD medicine?
Contact the prescribing clinician promptly with the active ingredient, dose and formulation. Follow any preconception plan already agreed, and do not make a sudden medicine change unless the clinician has told you to do so.
Which ADHD medicines are used in Australia?
Australian Prescriber and the Australian ADHD guideline identify methylphenidate, dexamfetamine and lisdexamfetamine as the main stimulant options for adults. Atomoxetine is a non-stimulant option in selected circumstances. Treatment choice should account for symptoms, everyday function, adverse effects and individual preferences.
| Active ingredient | Common Australian examples | What fertility evidence can say | Pregnancy planning point |
|---|---|---|---|
| Dexamfetamine, also called dexamphetamine | Short-acting tablets | Australian product information states that human fertility data are not available. | Category B3. Product information advises avoiding pregnancy during treatment; current Australian guidance still calls for an individual benefit-risk discussion rather than a self-directed change. |
| Lisdexamfetamine | Vyvanse, long-acting capsules | A dedicated human fertility study has not established an effect on conception. | Category B3. Use in pregnancy requires an individual review of the expected benefits and possible risks. |
| Methylphenidate | Ritalin, Ritalin LA, Concerta and other brands | Australian product information reports no human fertility data. | Category D because observational first-trimester data identified a possible small fetal cardiac malformation signal. |
| Atomoxetine | Non-stimulant capsules used in selected situations | Direct human fertility evidence remains limited. | Category B3. Changing to a non-stimulant is not automatically safer and needs prescriber review. |
Australian pregnancy categories are not a ranking from safest to most dangerous. Category B does not automatically mean safer than category C, and category D does not mean a medicine is absolutely contraindicated. The active ingredient, dose, timing and individual circumstances still determine the discussion.
Product information can be more restrictive than the category alone. Read the current product information and clinical guidance together with the prescribing clinician rather than using one category as the complete answer.
Does ADHD medication affect ovulation, eggs or implantation?
No human study has shown that prescribed dexamfetamine, lisdexamfetamine or methylphenidate stops ovulation, damages egg quality or prevents implantation. The limitation is that these outcomes have not been studied directly enough to rule out every possible effect. Australian product information therefore describes human fertility data as absent or limited.
Side effects can still matter. ADHD medicines may affect appetite, weight, sleep, heart rate, blood pressure or mood. A substantial change in any of these areas deserves review, but it should not be treated as proof that the medicine has harmed an egg or caused infertility.
If cycles are irregular or no clear LH rise appears across repeated testing, follow the usual fertility assessment rather than assuming the prescription is the cause. The no LH surge guide explains missed surges, delayed ovulation and when unclear results need medical review.
What do the newest pregnancy studies add?
Pregnancy research cannot answer every fertility question, but it matters before conception because early exposure can occur before a pregnancy test turns positive. The newest evidence is mixed rather than simply reassuring or alarming.
A 2024 Western Australian study compared 547 people who continued dexamphetamine, 297 who stopped during pregnancy and 844 who had used ADHD medicine before pregnancy but were not dispensed it during pregnancy. Continuing dexamphetamine was not associated with a broad increase in adverse maternal or neonatal outcomes compared with stopping during pregnancy. However, the group not dispensed ADHD medicine during pregnancy had more favourable results for several outcomes. The authors said stopping before pregnancy may be advisable where possible, while stressing the observational design, exposure timing and inability to assess spontaneous pregnancy loss fully.
A 2025 Western Australian cohort compared 852 dexamphetamine-exposed pregnancies with 65 methylphenidate-exposed pregnancies. Most measured maternal and neonatal outcomes were comparable, but the methylphenidate group was small, so the study cannot establish that the medicines have identical risk.
A 2026 New South Wales cohort linked hospital and dispensing records for 312,697 births. Among 336 pregnancies with ADHD medicine use, gestational hypertension and gestational diabetes were more common than in matched unexposed pregnancies. Comparisons with 252 pre-pregnancy users reduced several estimates, and the researchers could not determine how much reflected medicine exposure rather than ADHD or related health factors.
International evidence adds context. UKTIS reports that early therapeutic amphetamine exposure has not been associated with an overall or cardiac major malformation increase, while methylphenidate retains a possible small cardiac signal. A 2025 systematic review of 12 cohort studies found mixed outcomes and supported individual benefit-risk discussion. Newer Nordic studies reported associations with miscarriage and preterm birth, but prescription records cannot prove every dose was taken and observational data cannot remove all differences in ADHD severity, health and other medicines.
These studies help clinicians discuss pregnancy exposure, but they do not create one direct fertility answer. For the person planning pregnancy, the decision still comes back to the medicine being taken, the support it provides in everyday life and what can be changed safely before conception.
When should you review ADHD medication before pregnancy?
Healthdirect recommends seeing a doctor about 3 to 6 months before trying to become pregnant. RANZCOG pre-pregnancy guidance also includes reviewing pre-existing conditions and current medicines before conception. That window gives you time to make a considered plan rather than a rushed change. If you are already trying, book the review now instead of waiting for a positive test.
Bring the box, a current medication list or a clear photo of the label. The appointment should cover the active ingredient, dose, short-acting or long-acting formulation, how symptoms change when a dose is missed, blood pressure, appetite, weight, sleep, mood, driving, work safety, other medicines and any non-prescribed stimulant use.
Ask for a written plan that explains what remains unchanged while trying, what would trigger a dose review, who to contact after a positive pregnancy test and which symptoms need earlier advice. This is more useful than an arbitrary instruction to wait one cycle or a fixed number of days.
Should you stop, reduce, switch or continue treatment?
There is no universal washout period for ADHD medication before conception. Drug clearance is only one part of the decision. A treatment change also needs to account for concentration, impulsivity, emotional regulation, driving, work, nutrition, appointment attendance and the safe use of other medicines.
Australian Prescriber notes that psychostimulants and atomoxetine do not usually require a taper for pharmacological safety. That does not make a sudden self-directed change a good plan. A gradual reduction may lessen lethargy or loss of motivation, while Australian consumer medicine information still advises checking with the prescriber before stopping or changing the dose.
Switching is not automatically safer. A new medicine introduces a new response, new adverse effects and its own evidence gaps. Some people continue the same treatment, some reduce the dose, some change formulation, and some trial a period without medicine when the expected benefits outweigh the functional risks.
Neuroaffirming supports can make any agreed plan easier to manage. Useful options may include visible routines, reminders, simplified meals, appointment notes, workplace adjustments, ADHD-informed psychological therapy and involving a trusted person in important discussions.
Can ADHD stimulant medicine affect sperm or male fertility?
A 2026 multicentre study compared 388 stimulant-exposed men with 776 matched men who also had ADHD but were not recently prescribed a stimulant. Median semen volume was 2.70 mL in the exposed group and 2.95 mL in the comparison group. Sperm concentration, motility, total sperm count and total motile sperm count were not significantly different.
The study did not measure pregnancy rates or time to pregnancy, and it could not confirm dose, adherence or long-term exposure in detail. The findings are reassuring about the main semen-quality measures, but they do not prove that every person will have the same result.
If conception is taking longer than expected, a male fertility assessment is more informative than assuming the prescription is responsible.
Using ovulation tests and pregnancy tests while taking ADHD medicine
Standard ADHD medicines do not contain luteinising hormone or human chorionic gonadotrophin, so they are not what an ovulation test or pregnancy test is designed to detect. Unexpected results can reflect timing, diluted urine, starting too late, reading outside the stated window or expecting one home test to confirm ovulation.
Compare ovulation tests in Australia before choosing a format. Ovulation test strips suit repeated testing across several days, while midstream ovulation tests offer direct testing without a collection cup.
A positive LH test helps identify a hormonal surge before likely ovulation. It does not confirm that an egg was released or show whether ADHD medicine has affected fertility. The fertile window guide explains how LH timing fits with the days when conception is possible.
When a period is due or late, move from LH tracking to an hCG pregnancy test. If results remain unclear or you have been trying for the recommended timeframe, the Australian fertility referral guide explains when clinical assessment may be more useful than buying more tests.
What should you do after a positive pregnancy test?
Contact the prescribing clinician promptly and provide the active ingredient, dose, formulation, last dose and any other medicines or supplements. Follow the plan agreed before conception if you have one.
Do not assume that the medicine must be stopped that day, and do not assume it should continue unchanged until the next routine appointment. The clinician may keep the treatment stable, adjust it, arrange additional monitoring or involve the maternity-care team. The guide to what to do after a positive pregnancy test in Australia covers the wider early-pregnancy care pathway.
When should you seek prompt medical advice?
Contact the prescriber sooner if a medicine change causes a marked loss of function, unsafe driving or work risk, severe mood change, major sleep disruption or symptoms you cannot manage with the agreed plan. Call 000 for a life-threatening emergency such as collapse, a seizure, severe breathing difficulty or immediate risk of self-harm.
Frequently Asked Questions About ADHD Medication and Fertility in Australia
Does dexamphetamine affect female fertility?
Current human evidence does not establish that prescribed dexamfetamine causes female infertility. Australian product information says human fertility data are unavailable, so irregular cycles or difficulty conceiving should be assessed through the usual fertility pathway rather than attributed to the medicine alone.
Can Vyvanse affect ovulation or conception?
A dedicated human fertility study has not established whether lisdexamfetamine changes ovulation or time to pregnancy. Current evidence does not show that it prevents conception, but pregnancy planning should still be reviewed before treatment is changed.
Does Ritalin or Concerta affect fertility?
Human fertility data are unavailable for methylphenidate. Its pregnancy information differs from dexamfetamine and lisdexamfetamine because of a possible small fetal cardiac malformation signal, so Ritalin or Concerta should have a medicine-specific preconception review.
Can ADHD medication affect sperm or semen quality?
A 2026 multicentre study found modestly lower semen volume among stimulant users, while sperm concentration, motility, total count and total motile count were not significantly different. It did not measure pregnancy rates or time to pregnancy.
How long before pregnancy should ADHD medicine be stopped?
There is no universal washout period. Drug clearance is only one part of the decision; the prescriber also needs to consider the medicine, dose, symptoms, daily safety and whether a planned reduction would be appropriate.
What should you do if you become pregnant while taking ADHD medicine?
Contact the prescriber promptly with the active ingredient, dose and formulation. Do not assume treatment must stop immediately, and do not continue unchanged without following the plan agreed for early pregnancy.
Next Steps in Australia
Start with the clinician who prescribes your ADHD medicine. Bring the box, a current medicine list or a clear label photo and ask for a written plan covering trying to conceive, a positive pregnancy test, dose changes and what to do if symptoms or side effects change.
Use LH and hCG tests for fertile-window timing and pregnancy detection, not to judge medication safety. If cycles remain unclear, health side effects are significant or conception is taking longer than expected, move from home tracking to a GP, prescribing clinician or fertility service.
Last reviewed: 19 August 2026
Next scheduled review: August 2027
References
Fertility2Family articles are researched using Australian Government health guidance, professional clinical recommendations, medicine-specific product information, specialist teratology reviews and peer-reviewed medical literature. The references below were used to research and medically review this article and provide additional reading for readers who want to explore the evidence in more detail.
Australian Prescriber. Pharmacological management of attention deficit hyperactivity disorder in adults
Summarises current Australian adult ADHD medicines, monitoring, discontinuation principles and shared pregnancy decision-making for dexamfetamine, lisdexamfetamine, methylphenidate and atomoxetine.
Australasian ADHD Professionals Association. Australian Evidence-Based Clinical Practice Guideline for ADHD
Australian clinical guidance supporting individual treatment decisions that consider symptoms, everyday functioning, quality of life, potential benefits, adverse effects and personal preferences.
RANZCOG. Pre-Pregnancy Counselling (C-Obs 3a)
Current Australian and New Zealand preconception guidance covering health-condition review, current medicines, pregnancy planning and referral before conception.
Centre of Perinatal Excellence. ADHD in pregnancy
Australian perinatal ADHD guidance on neuroaffirming support, mental health planning and discussing prescribed medicine changes with a doctor rather than stopping treatment alone.
Therapeutic Goods Administration. Australian categorisation system for prescribing medicines in pregnancy
Explains why Australian pregnancy categories are not a simple safety ranking and why the full product information and individual benefit-risk assessment still matter.
Therapeutic Goods Administration. Methylphenidate – use in pregnancy
Details methylphenidate’s category D classification after observational first-trimester evidence identified a possible small fetal cardiac malformation signal.
Australian Commission on Safety and Quality in Health Care. Aspen Dexamfetamine
Current Australian medicine information for dexamfetamine, including pregnancy advice, active-ingredient details, monitoring and the absence of available human fertility data.
Australian Commission on Safety and Quality in Health Care. Vyvanse
Current Australian lisdexamfetamine product and consumer information covering conception planning, pregnancy, dose-change advice and the lack of a dedicated human fertility study.
Australian Commission on Safety and Quality in Health Care. Ritalin
Current Australian methylphenidate information covering human fertility-data limitations, category D pregnancy advice and the need for medicine-specific clinical review.
Healthdirect Australia. Planning for your pregnancy
Australian preconception guidance recommending an early GP review of medicines, health conditions, supplements and pregnancy plans, ideally before trying to conceive.
Archives of Women’s Mental Health. Investigating maternal and neonatal health outcomes associated with continuing or ceasing dexamphetamine treatment for women with attention-deficit hyperactivity disorder during pregnancy: a retrospective cohort study
Western Australian cohort comparing dexamphetamine continuation, cessation during pregnancy and preconception use without pregnancy dispensing, with limitations around exposure timing and pregnancy-loss assessment.
Neurodiversity. Maternal and Neonatal Outcomes Associated with the use of Dexamphetamine or Methylphenidate in Pregnancy: A Retrospective Cohort Study
Western Australian comparison of dexamphetamine and methylphenidate exposure, reporting broadly comparable measured outcomes while noting the small methylphenidate group.
Archives of Women’s Mental Health. Attention-deficit/hyperactivity disorder medication use and cardiometabolic conditions in pregnancy: a population-based cohort study
New South Wales linked-data study examining gestational hypertension, pre-eclampsia and gestational diabetes while testing how underlying ADHD and related factors may influence observed associations.
UK Teratology Information Service. Use of therapeutic amfetamines in pregnancy
Specialist UK evidence review for therapeutic dexamfetamine and lisdexamfetamine exposure, covering early-pregnancy malformation data, preterm-birth findings and individual risk-benefit assessment.
UK Teratology Information Service. Use of methylphenidate in pregnancy
Specialist UK review of methylphenidate pregnancy evidence, including the possible cardiac malformation and miscarriage signals and the risks of destabilising effective treatment.
Archives of Women’s Mental Health. Maternal and offspring outcomes associated with prescribed ADHD medication in pregnancy: a systematic review
A 2025 systematic review of 12 cohort studies showing mixed observational findings and supporting an individual discussion of treatment benefits, potential risks and remaining uncertainty.
JAMA Psychiatry. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium
Large international cohort underlying the possible small methylphenidate cardiac malformation signal and finding no comparable congenital-malformation association for amphetamine exposure.
Psychological Medicine. Attention-deficit hyperactivity disorder medication use in pregnancy and risk of miscarriage
Norwegian register study reporting an association between filled ADHD medicine prescriptions and miscarriage while acknowledging that dispensing records may not equal actual use.
Paediatric and Perinatal Epidemiology. Attention-Deficit/Hyperactivity Disorder Medication Use in Pregnancy and Risk of Preterm Birth: A Population-Based Cohort Study
Nordic population cohort examining medicine-exposure timing and duration in relation to preterm birth, with modest associations that cannot establish individual causation.
International Journal of Impotence Research. Attention-deficit/hyperactivity disorder stimulant use is associated with reduced semen volume in reproductive-age men: a multi-center analysis
A 2026 multicentre study finding modestly lower semen volume with stimulant exposure but no significant differences in sperm concentration, motility or total counts.